CAMBRIDGE, Mass.--(BUSINESS WIRE)--GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new target intervention pathways, today announced an investment by Horizon Healthcare Services, Inc. (New Jersey). The investment supports a strategic collaboration between the companies and enables further development and validation of novel, cloud-based solutions at the intersection of precision medicine and population health.
Horizon joins previously announced Series C investors Celgene Corporation, Alexandria Real Estate Equities, and Gi Global Health Fund LP and investors in prior rounds, Cambia Health Solutions, California’s Heritage Provider Network, and Japan’s Mitsui & Co. U.S. subsidiary (“Mitsui USA”). Both Horizon and Cambia are affiliated with Blue Cross and Blue Shield companies.
GNS is at the forefront of the precision medicine movement, applying its patented causal machine learning and simulation platform, REFS™ (Reverse Engineering and Forward Simulation), to unlock value from increasingly rich streams of patient data, such as from electronic medical records, mobile health devices, medical and pharmacy claims, genomics, consumer behavior, and more. When applied to population health, precision medicine can identify individuals at risk, individuals who can most benefit from specific health interventions, and match individuals to the most effective intervention. The result is improved health outcomes and reduced healthcare costs – a win for health plans, employers, patients, and healthcare providers.
“The GNS causal machine learning platform applies the most advanced form of analytics to mainstream data sources, such as claims and electronic medical records,” said Dr. Minalkumar A. (Minal) Patel, Senior Vice President and Chief Strategy Officer of Horizon Blue Cross Blue Shield of New Jersey. “This breakthrough approach very precisely predicts individual risk, revealing opportunities to intervene on a timeline that delivers value. When it is applied to emerging data streams, such as genomic and mobile device data, causal machine learning has the power to take population health to the next level.”
“Horizon is emerging nationally as a leading voice in the movement to rethink population health management,” said Colin Hill, CEO and Co-founder of GNS. “Causal machine learning and simulation applied to precision medicine eliminates guesswork in population health management – whether it’s medication, a treatment plan, or a nudge from a health plan for preventive care, it is now possible to know the value and efficacy of an intervention for a specific individual, as well as an entire population.”
About GNS Healthcare
GNS Healthcare applies causal machine learning technology to predict which treatments will work for which patients, improving individual patient outcomes and the health of populations, while reducing costs. The GNS technology is based on its MeasureBase™ data integration architecture and patented REFS™ (Reverse Engineering and Forward Simulation) causal inference and simulation engine. Health plans, bio-pharmaceutical companies, healthcare providers, foundations, academic medical centers, and employers use these cloud-based solutions to solve pressing and costly problems including metabolic syndrome, medication adherence, end-of-life care, preterm birth, personalized care pathways in specialty care and diabetes, new drug target discovery, patient stratification in clinical trials, and more. GNS solutions focus on reducing adverse events, slowing disease progression, and improving therapeutic effectiveness through precision matching that maximizes impact on individual patient health outcomes while reducing wasteful spending and downstream medical costs.
Discovering what works, and for whom.
